Myasthenia gravis
MONDO:0009688Myasthenia gravis (MG) is a rare, clinically heterogeneous, autoimmune disorder of the neuromuscular junction characterized by fatigable weakness of voluntary muscles.
Also known as: acquired myasthenia, autoimmune myasthenia gravis, myasthenia gravis, MG
198 clinical trials for this condition and its sub-types, 159 tagged with Myasthenia gravis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Myasthenia gravis
-
Juvenile myasthenia gravis 2 trials
-
Adult-onset myasthenia gravis 0 trials
-
Myasthenia, limb-girdle, autoimmune 0 trials
-
Neonatal myasthenia gravis 0 trials
-
Transient neonatal myasthenia gravis 0 trials
-
New drug batoclimab aims to ease muscle weakness in myasthenia gravis
Disease control Stopped earlyThis phase 3 trial tests batoclimab, a drug that blocks certain antibodies, in 240 adults with generalized myasthenia gravis (gMG). The study measures if batoclimab improves daily activities and muscle strength compared to a placebo. Participants receive injections weekly or bi-w…
Phase 3 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Experimental CAR t therapy for severe muscle weakness hits early hurdle
Disease control Stopped earlyThis early trial tested an experimental drug called HN2301, a type of CAR T cell therapy made inside the body, for people with refractory myasthenia gravis — a condition causing severe muscle weakness that doesn't respond well to standard treatments. The study planned to enroll 9…
Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Myasthenia gravis drug trial halted early – only 6 patients enrolled
Disease control Stopped earlyThis study tested tolebrutinib, an oral drug, in adults with moderate-to-severe generalized myasthenia gravis. The trial was a Phase 3, double-blind, placebo-controlled study that planned to enroll many participants but was terminated early with only 6 people enrolled. Because it…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 26, 2026 14:27 UTC
-
Abandoned trial: only 2 patients tested for stomach relief in muscle disease
Symptom relief Stopped earlyThis small, early-stage trial tested whether adding ondansetron (an anti-nausea drug) to pyridostigmine (a standard myasthenia gravis treatment) could reduce stomach side effects like nausea, vomiting, or diarrhea. Only 2 people with anti-AchR positive myasthenia gravis were enro…
Phase 2 • Sponsor: DAS-MG, Inc • Aim: Symptom relief
Last updated Jun 26, 2026 15:47 UTC